articleTop 1% cited
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
The Lancet Oncology · 2016 · Vol. 17(11) · pp. 1497–1508
Corey J. Langer✉(University of Pennsylvania)Shirish M. Gadgeel(The Barbara Ann Karmanos Cancer Institute)Hossein Borghaei(Fox Chase Cancer Center)Vassiliki A. Papadimitrakopoulou(The University of Texas MD Anderson Cancer Center)Amita Patnaik(South Texas Accelerated Research Therapeutics)Steven PowellRyan D. Gentzler(University of Virginia)Renato Martins(University of Washington)James Stevenson(Cleveland Clinic)Shadia I. Jalal(Indiana University School of Medicine)Amit Panwalkar(Fargo VA Health Care System)James Chih‐Hsin Yang(National Taiwan University Hospital)Matthew A. Gubens(University of California, San Francisco)Lecia V. Sequist(Harvard University)Mark M. Awad(Dana-Farber Cancer Institute)Joseph Fiore(Merck & Co., Inc., Rahway, NJ, USA (United States))Yang Ge(Merck & Co., Inc., Rahway, NJ, USA (United States))Harry Raftopoulos(Merck & Co., Inc., Rahway, NJ, USA (United States))Leena Gandhi(Dana-Farber Cancer Institute)
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research StudiesPemetrexedPembrolizumabCarboplatinMedicineInternal medicineOncologyLung cancerChemotherapyCohortResponse Evaluation Criteria in Solid Tumors
Citations
1,385
FWCI
105.28
field-weighted impact
References
29
Percentile
100%
vs. same field & year
Citations per year
Cited by
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2018 · 6,460 citations
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Cancers · 2020 · 1,166 citations
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment
Frontiers in Immunology · 2019 · 832 citations
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
Frontiers in Oncology · 2018 · 652 citations
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
The Lancet Oncology · 2017 · 1,350 citations
Regulation and Function of the PD-L1 Checkpoint
Immunity · 2018 · 2,208 citations
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
European Journal of Cancer · 2017 · 555 citations
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Mayo Clinic Proceedings · 2019 · 2,172 citations
References
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 9,391 citations
On closed testing procedures with special reference to ordered analysis of variance
Biometrika · 1976 · 1,392 citations
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 8,491 citations
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
The Lancet · 2015 · 6,477 citations
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Cancer Cell · 2015 · 1,477 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.